Pall Biotech is the newest business unit of Pall Corporation, the international filtration, separation and purification company
Mario Philips, VP and general manager of Pall Biotech
Pall Corporation, a filtration, separation and purification company, has announced the launched of Pall Biotech, the newest business unit within Pall Life Sciences division.
The company said the branding aims to reflect an important strategic direction for the business. The update will not impact current or prospective company operations.
“As the lines between the biopharmaceutical and biotechnology sectors continue to merge, our commitment is stronger than ever to develop and deliver end-to-end capabilities with cutting-edge technologies and services. The name Pall Biotech reflects a more focused approach to serving these high-growth market segments,” Mario Philips, VP and general manager of Pall Biotech, explained.
Philips said the new business unit is dedicated to reducing costs while increasing efficiency and quality, for today’s developer of sensitive biologic products, including mAbs, recombinant proteins, viral vaccines, and cell and gene therapies.
Critical partnerships in the industry and alignment with regulatory agencies will play a key role in improving both the integrated and stand-alone elements of the Pall Biotech total bioprocessing solutions portfolio.
Martin Smith, chief technology officer of Pall Corporation, commented: “Pall Biotech does not make drugs; we enable drug manufacturers with rapid transition from pre-clinical to commercial manufacturing."
The Pall Biotech portfolio comprises standard configurable single-use, stainless steel and hybrid technologies for fed-batch and continuous processes across upstream, downstream and formulation and filling applications.
The company said each customer is fully supported by Pall Biotech experts at both a local and global level.